Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.

Orlandini M, Galvagni F, Bardelli M, Rocchigiani M, Lentucci C, Anselmi F, Zippo A, Bini L, Oliviero S.

Oncotarget. 2014 May 15;5(9):2750-60.

2.

Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.

Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, Lööf J, Trendelenburg G, Essand M, Pontén F, Smits A, Dimberg A.

Cancer Res. 2015 Nov 1;75(21):4504-16. doi: 10.1158/0008-5472.CAN-14-3636. Epub 2015 Sep 11.

PMID:
26363010
3.

A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.

Dai F, Chen Y, Song Y, Huang L, Zhai D, Dong Y, Lai L, Zhang T, Li D, Pang X, Liu M, Yi Z.

PLoS One. 2012;7(12):e52162. doi: 10.1371/journal.pone.0052162. Epub 2012 Dec 27.

4.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

5.

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ.

Mol Cancer Ther. 2012 Mar;11(3):649-59. doi: 10.1158/1535-7163.MCT-11-0575. Epub 2011 Dec 21.

7.

The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.

Kao YC, Jiang SJ, Pan WA, Wang KC, Chen PK, Wei HJ, Chen WS, Chang BI, Shi GY, Wu HL.

PLoS One. 2012;7(12):e51647. doi: 10.1371/journal.pone.0051647. Epub 2012 Dec 18.

8.

Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.

Liu YR, Guan YY, Luan X, Lu Q, Wang C, Liu HJ, Gao YG, Yang SC, Dong X, Chen HZ, Fang C.

Biomaterials. 2015 Feb;42:161-71. doi: 10.1016/j.biomaterials.2014.11.039. Epub 2014 Dec 16.

PMID:
25542804
9.

A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth.

Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K, Bader BL.

Blood. 2003 Jul 1;102(1):184-91. Epub 2003 Feb 27.

10.

Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.

Bhuvaneswari R, Yuen GY, Chee SK, Olivo M.

Lasers Surg Med. 2011 Sep;43(7):651-62. doi: 10.1002/lsm.21109.

PMID:
22057493
11.

Norcantharidin anti-angiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer.

Yu T, Hou F, Liu M, Zhou L, Li D, Liu J, Fan Z, Li Q.

Asian Pac J Cancer Prev. 2012;13(2):499-503.

12.

Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ.

Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.

13.

Flow cytometric identification of CD93 expression on naive T lymphocytes (CD4(+)CD45RA (+) cells) in human neonatal umbilical cord blood.

Ikewaki N, Yamao H, Kulski JK, Inoko H.

J Clin Immunol. 2010 Sep;30(5):723-33. doi: 10.1007/s10875-010-9426-1. Epub 2010 May 29.

PMID:
20512406
14.

Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.

Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W.

Int J Oncol. 2012 May;40(5):1501-14. doi: 10.3892/ijo.2011.1314. Epub 2011 Dec 21.

PMID:
22200632
15.

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T.

Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1.

16.

New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential.

Conconi MT, Marzaro G, Guiotto A, Urbani L, Zanusso I, Tonus F, Tommasini M, Parnigotto PP, Chilin A.

Invest New Drugs. 2012 Apr;30(2):594-603. doi: 10.1007/s10637-010-9621-1. Epub 2010 Dec 24.

PMID:
21184131
17.

Orally Administered Mucolytic Drug l-Carbocisteine Inhibits Angiogenesis and Tumor Growth in Mice.

Shinya T, Yokota T, Nakayama S, Oki S, Mutoh J, Takahashi S, Sato K.

J Pharmacol Exp Ther. 2015 Sep;354(3):269-78. doi: 10.1124/jpet.115.224816. Epub 2015 Jun 30.

PMID:
26126534
18.

Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development.

Desselle A, Chaumette T, Gaugler MH, Cochonneau D, Fleurence J, Dubois N, Hulin P, Aubry J, Birklé S, Paris F.

PLoS One. 2012;7(11):e45423. doi: 10.1371/journal.pone.0045423. Epub 2012 Nov 26.

19.

Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.

de Aguiar RB, Parise CB, Souza CR, Braggion C, Quintilio W, Moro AM, Navarro Marques FL, Buchpiguel CA, Chammas R, de Moraes JZ.

Cancer Lett. 2016 Feb 28;371(2):151-60. doi: 10.1016/j.canlet.2015.11.030. Epub 2015 Dec 3.

PMID:
26655277
20.

Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.

Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP.

Carcinogenesis. 2012 Feb;33(2):385-93. doi: 10.1093/carcin/bgr282. Epub 2011 Dec 1.

Items per page

Supplemental Content

Write to the Help Desk